94 results
8-K
EX-99.1
RGLS
Regulus Therapeutics Inc
9 May 24
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
4:15pm
was well tolerated with no safety findings of concern. Greater biological activity of RGLS8429 was observed at 2 mg/kg based on urinary polycystin levels … of the Phase 1 SAD study in September 2022. The Phase 1 SAD study demonstrated that RGLS8429 has a favorable safety and PK profile. RGLS8429 was well
8-K
EX-99.1
RGLS
Regulus Therapeutics Inc
21 Mar 24
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
4:18pm
with no safety findings of concern. Greater biological activity of RGLS8429 was observed at 2 mg/kg based on urinary polycystin levels compared to 1mg/kg … will further explore at higher doses in cohorts 3 and 4.
The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety
8-K
EX-99.2
RGLS
Regulus Therapeutics Inc
14 Mar 24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
4:57pm
study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult … the sample size to up to 30 patients. In addition to PC1 and PC2 and safety, imaging biomarkers will also be evaluated.
In the second cohort, 14 patients
8-K
EX-99.1
5jmqvlvkij8g9d9m26
9 Nov 23
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
msbjzh
8 Aug 23
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
gn6yjaiirg391
11 May 23
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
4:16pm
8-K
EX-99.1
uti43hpr31qumhi 5me
10 Nov 22
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates
4:15pm
8-K
EX-99.1
7l1zsmr3vnl2e9wxrl
11 Aug 22
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
4:33pm
8-K
EX-99.1
3odu5koi8i598ks2zkgx
12 May 22
Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
4:31pm
8-K
EX-99.1
l4h2ykd4c 9dh28dwfx
18 Oct 21
Other Events
6:06am